-
Company Profile
![]()
Impel Pharmaceuticals Inc – Company Profile
Impel Pharmaceuticals Inc (Impel), formerly Impel NeuroPharma Inc, is a clinical-stage biotechnology company that develops intranasal drug treatments for central nervous system disorders. The company’s pipeline product portfolio such as Trudhesa (formerly known as INP104), a liquid solution for the treatment of acute migraine, and INP105, olanzapine for the treatment of bipolar disorder. It also develops Precision Olfactory Delivery technology, a nasal drug delivery platform that delivers drugs for improved biodistribution. Impel’s products are used for the treatment of pain,...
Add to Basket -
Product Insights
![]()
Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. This is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington Disease pipeline market research report provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous...
-
Product Insights
![]()
Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of amyotrophic lateral sclerosis include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss. The Amyotrophic Lateral Sclerosis pipeline market research report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type....
-
Sector Analysis
![]()
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Superoxide dismutase is used for treating pain and swelling (inflammation) caused by osteoarthritis, sports injuries, rheumatoid arthritis, interstitial cystitis, gout, cancer, lung problems in newborns, and poisoning caused by a weed-killer called paraquat. The Superoxide Dismutase pipeline market research report provides comprehensive information on the Superoxide Dismutase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its...
-
Product Insights
![]()
Traumatic Brain Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping, and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems. The traumatic brain injury drugs in development market research report provides an overview...
-
Product Insights
![]()
Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes, and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation, and cardiovascular diseases. The Dementia Drugs in Development market research report provides an overview of the Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia,...
-
Product Insights
![]()
Alzheimer’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alzheimer's disease is a progressive, degenerative condition causing damage to memory and behavior due to the attack on the neurons. Predisposing factors include age, heredity, cardiovascular diseases or diabetes, and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability, and aggressiveness. The Alzheimer’s Disease Drugs in Development market research report provides an overview of the Alzheimer's Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alzheimer's Disease, complete with analysis by stage of development, drug...
-
Sector Analysis
![]()
Migraine Drug Market Size, Share & Trends Analysis and Forecast by Strategic Competitor Assessment, Market Characterization, Unmet Needs, Clinical Trial Mapping and Implications 2020 – 2030
The global sales for migraine drugs have been valued at $4.6 billion in 2020 with a CAGR of more than 9%. The US has dominated the migraine market, contributing to more than 80% of the sales in the seven major pharmaceutical markets (7MM) covered - the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. A high market share in US is attributed to the large migraine prevalent population, the costliness of branded drugs, and the number of...
-
Product Insights
![]()
Migraine Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Migraine Global Clinical Trials Review, H2, 2017" provides an overview of Migraine clinical trials scenario. This report provides top line data relating to the clinical trials on Migraine. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.